Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis.
Saved in:
| Title: | Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis. |
|---|---|
| Authors: | Lin S; Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, China.; Department of Endocrinology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China., Ou X; Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, China.; Department of Endocrinology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China., Cai L; Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, China.; Department of Endocrinology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China., Huang W; Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, China.; Department of Endocrinology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China., Wen J; Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, China. junpingwen@163.com.; Department of Endocrinology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China. junpingwen@163.com. |
| Source: | Journal of endocrinological investigation [J Endocrinol Invest] 2025 Sep; Vol. 48 (9), pp. 1951-1965. Date of Electronic Publication: 2025 Apr 30. |
| Publication Type: | Journal Article; Meta-Analysis; Systematic Review |
| Journal Info: | Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386 (Electronic) Linking ISSN: 03914097 NLM ISO Abbreviation: J Endocrinol Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
